MD Anderson is the first institution to address the interrelated problems of theft of intellectual property, violation of ethics of NIH peer review, and researchers’ failure to disclose foreign affiliations and sources of funding.
In April 2025, announcements from the two most influential biomedical agencies in the US, the FDA and the NIH, declared that both will seek to reduce and minimize animal-based testing and experimentation. These declarations sparked joy in some circles, and deep concern in others that was reflected in a 28% fall in the share price of Charles River Labs (NYSE: NYSE:CRL).
